Edrecolomab in Treating Patients With Stage II Colon Cancer

Summary

Randomized phase III trial to compare the effectiveness of surgery with or without monoclonal antibody therapy in treating patients who have stage II colon cancer. Monoclonal antibodies such as edrecolomab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. It is not yet known whether surgery to remove colon cancer is more effect with or without monoclonal antibody therapy.

Timeline

Start

1997-05

Primary completion

2003-07

Completion

—

Drugs

Indications